Skip to main content
COVID-19 In Vitro Diagnostic Devices and Test Methods Database

Scientific literature on COVID-19 Test Methods and Devices - detail

Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection.

Detection Principle
ImmunoAssay-Antibody
Target
IgG vs N protein (Abbott, Epitope, Mikrogen, Roche) , S protein (Virion-Serion), S1 domain alone (Euroimmun) or together with the S2 domain (DiaSorin); S1, S2, N (Virachip)
Testing Method Category
Mixed
Testing Method
kits
Testing Method - Additional Info
7 SARS-CoV-2 IgG assays (Abbott SARS-CoV-2 IgG, Wiesbaden, Germany; DiaSorin Liaison SARS-CoV-2 S1/2 IgG, DiaSorin, Dietzenbach, Germany; Epitope EDI Novel Coronavirus COVID-19 IgG ELISA Kit, Epitope Diagnostics, San Diego, CA, USA; Euroimmun Anti-SARS-CoV-2 ELISA (IgG), EUROIMMUN AG, Lübeck, Germany; Mikrogen recomWell SARS-CoV-2 IgG, Mikrogen GmbH, Neuried, Germany; SARS-CoV-2 ViraChip IgG Test, Viramed Biotech AG, Planegg, Germany; and SERION ELISA agile SARS-COV-2 IgG, Institute Virion-Serion GmbH, Würzburg, Germany), as well as 1 total SARS-CoV-2 antibody test (Roche Elecsys Anti-SARS-CoV-2, Roche Diagnostics, Mannheim, Germany)
Reported Performance
Sensitivity vs PCR: 96.2% (Abbott), 84.6% (Diasorin), 80.8% (Epitope), 80.8% (Euroimmun), 88.5% (Mikrogen), 88.5% (Roche), 88.5% (Viramed), 96.2% (Virion-Serion); Sensitivity vs PRNT: 96.3% (Abbott), 88.9% (Diasorin), 92.6% (Epitope), 88.9% (Euroimmun), 96.3% (Mikrogen), 96.3% (Roche), 96.3% (Viramed), 96.3% (Virion-Serion); Specifiicty: 99% (Abbott), 96% (Diasorin), 100% (Epitope), 97% (Euroimmun), 98% (Mikrogen), 99% (Roche), 99% (Viramed), 100% (Virion-Serion)
Sample Size
37 samples
Peer-reviewed
yes

The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements